Navigation Links
Damon Runyon Cancer Research Foundation awards $2.25M to 5 top young clinical investigators

New York, NY -- The Damon Runyon Cancer Research Foundation named 5 new Damon Runyon Clinical Investigators at its May 2008 Clinical Investigator Award Committee review. The recipients of this prestigious, three-year award are outstanding early career physician-scientists conducting patient-oriented cancer research at major research centers under the mentorship of the nation's leading scientists and clinicians. Each will receive $450,000 to support the development of his or her cancer research program. The Clinical Investigator Award program is specifically intended to help address the worrisome shortage of physicians capable of translating scientific discovery into new breakthroughs for cancer patients. In partnerships with founding sponsor Eli Lilly and Company, and with Siemens Medical Solutions, Novartis and Genentech, the Damon Runyon Cancer Research Foundation has committed more than $30 million to support the careers of 44 physician-scientists across the United States since 2000.

2008 Clinical Investigator Awardees

  • Ronald J. Buckanovich, MD, PhD

    By combining tumor cells and embryonic stem cells, Dr. Buckanovich has developed a new animal model of ovarian cancer that develops abundant tumor blood vessels, or vasculature. He is using this model to first characterize molecular markers of tumor vasculature, and then therapeutically target them with antibodies coupled to toxic nanoparticles. He also seeks to identify and characterize a population of cells, cancer stem cells, which play a critical role in tumor establishment and growth. These discoveries could lead to highly effective targeted therapies. Dr. Buckanovich works under the mentorship of Daniel F. Hayes, MD, and Max S. Wicha, MD, at the University of Michigan, Ann Arbor, Michigan.

  • Andrew T. Chan, MD, MPH

    Dr. Chan is developing molecular "smart" probes and novel imaging techniques for earlier and improved detection of colorectal cancer. He will soon be testing this promising technology in clinical trials. In addition, this work has the potential to accelerate the discovery and development process for therapeutic and chemopreventative agents in colorectal cancer. Dr. Chan works under the mentorship of Charles S. Fuchs, MD, MPH, and Ralph Weissleder, MD, PhD, at the Massachusetts General Hospital, Boston, Massachusetts.

  • Rachael A. Clark, MD, PhD

    Dr. Clark is investigating the role of the immune system in controlling squamous cell carcinomas of the skin. She has identified new mechanisms by which these skin tumors evade the immune system: disruption of T cell homing and recruitment of regulatory T cells. Her studies focus on developing new therapies for effective treatment of these cancers. Dr. Clark works under the mentorship of Thomas S. Kupper, MD, at Brigham and Women's Hospital, Boston, Massachusetts.

  • Vassiliki Karantza-Wadsworth, MD, PhD

    Autophagy is a process of "cellular self-digestion" that is used by both normal cells and tumor cells as a survival mechanism in times of metabolic stress, such as nutrient and oxygen deprivation. Dr. Karantza-Wadsworth is examining the role of autophagy in tumor cell survival and responsiveness to chemotherapy. She is performing preclinical and clinical studies modulating autophagy in breast cancer, which could lead to improved patient response to treatment. Dr. Karantza-Wadsworth works under the mentorship of Eric H. Rubin, MD, at UMDNJ/Robert Wood Johnson Medical School, New Brunswick, New Jersey.

  • Elahe A. Mostaghel, MD, PhD

    Suppression of the hormone testosterone is currently the most effective treatment for advanced prostate cancer; however, tumors frequently develop resistance to this therapy. Dr. Mostaghel is defining key mechanisms underlying this resistance to hormone treatment. Her goal is to develop novel treatments for prostate cancer that can be rapidly moved into the clinic. Dr. Karantza-Wadsworth works under the mentorship of Peter S. Nelson, MD, at the Fred Hutchinson Cancer Research Center, Seattle, Washington.


Contact: Yung S. Lie, PhD
Damon Runyon Cancer Research Foundation

Related medicine news :

1. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators
2. Damons Grill Completes Move to Trans Fat-Free Menu
3. CT Screens for Lung Cancer Not a Cure-All
4. Pro Baseball Helps Keep Skin Cancer From Scoring
5. Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Irelands First Nationwide Cervical-Cancer Screening Program
6. American Academy of Dermatology, Major League Baseball and Major League Baseball Players Association Play Sun Smart(TM) to Strike Out Skin Cancer
7. Lack of CHFR gene expression sets stage for breast cancer
8. 10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain
9. Vitamin D May Promote Colon Cancer Survival
10. Study links vitamin D to colon cancer survival
11. Cancer Drug Gleevec Linked to Muscle Damage
Post Your Comments:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: